Blueprint Medicines: Q1 Earnings Insights

 

Blueprint Medicines BPMC reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM.

Here's what investors need to know about the announcement.

Earnings

Blueprint Medicines beat estimated earnings by 7.73%, reporting an EPS of $-1.79 versus an estimate of $-1.94.

Revenue was up $41.16 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.66 which was followed by a 7.75% drop in the share price the next day.

Here's a look at Blueprint Medicines's past performance:

 

Quarter Q4 2021 Q3 2021 Q2 2021 Q1 2021
EPS Estimate -1.65 -1.63 -1.86 -1.86
EPS Actual -0.99 -2 -1.86 -1.72
Revenue Estimate 102.69M 42.47M 19.01M 17.25M
Revenue Actual 107.02M 24.19M 27.30M 21.58M

To track all earnings releases for Blueprint Medicines visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...